



Between Sustainability and Innovation

Thursday, 28 November

14.00 – 14.30 **Opening remarks**
M.C. Fantini IG-IBD, *AMICI Onlus*

LECTURE

Introduction: M.C. Fantini

14.30-15.00 **Standards of Quality of Care for IBD**
G. Fiorino

SESSION I ORAL COMMUNICATIONS

Chairs: L. Biancone, G. Dragoni

15.00-15.10 **The effectiveness of Risankizumab as induction therapy for Crohn's disease: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)**

F.S. Macaluso

15.10-15.20 **Effectiveness and safety of Upadacitinib in patients with Ulcerative Colitis: preliminary data of UPAREAL-UC Multicenter IG-IBD Study**

F. Desideri

15.20-15.30 **Real-life effectiveness and safety of Tofacitinib and Vedolizumab as a second-line therapy in anti-TNFS experienced patients with Ulcerative Colitis: a multicenter cohort IGIBD study (VE2TO-UC)**

D. Noviello

15.30-15.40 **Effectiveness and safety of Risankizumab in a large Italian cohort of Crohn's disease patients: preliminary results from the RESOLVE IGIBD study**

F. Di Vincenzo

15.40-15.50 **The value of Tofacitinib for the treatment of moderate to severe Ulcerative Colitis: two-years data from TOFA-UC, a SN-IBD study**

F.S. Macaluso

15.50-16.00 **Long-term effectiveness and safety of Ustekinumab in Crohn's disease: results from a large cohort study**

G. Mocchi

16.00-16.30 Coffee break

SESSION II SUSTAINABILITY IN IBD

Chairs: B. Barberio, P. Gionchetti

17.45-18.05 **Drug positioning**

A. Rispo

18.05-18.25 **Therapeutic cycling**

S. Onali

18.25-18.45 **Balancing patient needs and therapeutic targets**

C. Bezzio

18.45-19.00 Discussion



Friday, 29 November

BREAKFAST WITH THE EXPERTS: challenging clinical cases – extra ECM

07.40 – 08.20 **Clostridioides difficile and IBD** S. Ardizzone, F.S. Macaluso

07.40 – 08.20 **Refractory ulcerative proctitis** M. Daperno, F. Rizzello

LECTURE

Introduction: E. Calabrese

08.30 – 09.00 **Evolving IBD management: the convergence of Digital Telemonitoring, AI and smart technology**

C. Lees

SESSION III ORAL COMMUNICATIONS

Chairs: L. Lopetuso, S. Vetrano

09.00-09.10 **Enhanced transcription of human endogenous retroviruses and downregulation of TRIM28 in patients with Crohn's disease and Ulcerative Colitis**

D.G. Ribaldone

09.10-09.20 **INKT cell immunomodulation and mucosal healing by microbiota-derived lactate**

F. Strati

09.20-09.30 **Altered expression and enzymatic activity of Xanthine Oxidase in Inflammatory Bowel Disease**

A. Di Petrillo

09.30-09.40 **NRG1, a gene significantly detected from intestinal mucosa ECCDNA, may predict therapeutic response in Inflammatory Bowel Disease**

V. Emoli

09.40-09.50 **In silico target prediction and docking studies of JAK Inhibitors Tofacitinib, Filgotinib, and Upadacitinib reveal potential HDAC targets in IBD treatment**

A. Di Petrillo

09.50-10.00 **Protective effects of Adenosine deaminase RNA specific 1 in Ulcerative Colitis**

A. Iannucci

10.00 – 10.30 Coffee break

SESSION IV IBD SURGERY IN 2024

Chairs: M. Mineccia, M. Vecchi

11.30 – 11.50 **New surgical techniques**

A. Spinelli

11.50 – 12.10 **Pelvic surgery and fertility**

G. Luglio

12.10 – 12.30 **Tandem talk: what is a good surgeon for an “Ibdologist” and what is a good “Ibdologist” for a surgeon**

S. Saibeni, G.M. Sampietro

12.30 – 13.00 Discussion

13.00 – 13.45 Lunch



- 15.00-15.20 NEW TOPIC**
Chairs: S. Festa, O.M. Nardone
IBD healthcare for LGBTQIA+ patients
D. Pugliese
- 15.20-15.30 Open discussion

SESSION V ORAL COMMUNICATIONS
Chairs: F. Bossa, F. D'Amico

- 15.30-15.40 **A novel switching artificial intelligence to simultaneously convert different endoscopic enhancement modalities for accurate assessment of inflammation and prediction of outcomes in Ulcerative Colitis**
G. Santacroce
- 15.40-15.50 **Applicability of the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) to Ulcerative Colitis: preliminary data**
T. Innocenti
- 15.50-16.00 **Achieving disease clearance in Ulcerative Colitis: outcomes and predictors from advanced treatments**
C. Caranfil
- 16.00-16.10 **Real-world effectiveness of Tofacitinib on Ulcerative Colitis associated Spondyloarthritis (RETUCAS): a multicentre prospective study from the Italian Group for the study of Inflammatory Bowel Diseases (IG-IBD)**
F.S. Macaluso
- 16.10-16.20 **Upadacitinib in Ulcerative Colitis patients failure to other JAK inhibitors: insights from UPAREAL-UC multicenter IG-IBD study**
N. Bevilacqua
- 16.20-16.30 **Clinical outcome at 5 years of patients with Crohn's disease-related surgery different from Ileo-Colonic resection**
B. Neri
- 16.30 – 17.00 Coffee break

SESSION VI COLONIC DYSPLASIA AND CANCER
Chairs: M. Principi, S. Scaringi

- 17.00 – 17.20 **Epidemiology and pathogenesis**
S. Leedham
- 17.20 – 17.35 **How to do surveillance**
G.E. Tontini
- 17.35 – 18.05 **Endoscopic or surgical management of dysplasia?**
R. De Sire, M.M. Carvello
- 18.05 – 18.20 Discussion

18.30 – 19.45 ASSEMBLEA ORDINARIA DEI SOCI IG-IBD



Saturday, 30 November

SESSION VII ORAL COMMUNICATIONS

Chairs: D.G. Ribaldone, S. Renna

- 08.30-08.40 **Epithelial and not lamina propria neutrophil localization and intestinal barrier protein expression are innovative outcome predictors in Inflammatory Bowel Disease**
I. Zammarchi
- 08.40-08.50 **Human Extrachromosomal Circular DNA (ECCDNA) is a novel biomarker in Inflammatory Bowel Disease**
F. Di Vincenzo
- 08.50-09.00 **Analysis of immunological variables in ex vivo Tofacitinib-treated human biopsies from active Ulcerative Colitis patients to predict clinical response (the AVATAR study)**
M.C. Fantini
- 09.00-09.10 **Impact of advanced therapy on bowel urgency in Inflammatory Bowel Disease: a multicenter study**
F. D'Amico
- 09.10-09.20 **Frailty increases infection risk in patients with Inflammatory Bowel Disease treated with biologics**
E. Fuochi
- 09.20-09.30 **Prevalence and progression of metabolic-dysfunction associated steatotic liver disease in Inflammatory Bowel Disease: call for action on life style**
E. Bracciamà

LECTURE

Introduction: M.V. Lenti

09.30 -10.00 Will ChatGPT change our practice? Real opportunity or global risk?

P. Ellul

10.00 – 10.30 Coffee break

LECTURE

Introduction: A. Variola

11.45-12.15 Paediatric IBD: what's on the cutting edge

M. Aloï

SESSION VIII IBD INNOVATE

Chairs: S. Danese, G. Monteleone

- 12.15 – 12.35 **The next generation of IBD drugs**
A. Di Sabatino
- 12.35 – 12.55 **Immunobiologic rationale for combination therapy**
F.A. Caprioli
- 12.55 – 13.15 **Artificial intelligence in endoscopy**
M. Iacucci
- 13.15 – 13.30 Discussion
- 13.30 – 13.40 **Conclusions**